(Bloomberg) -- Roche Holding AG said an experimental breast-cancer treatment will get an expedited review from US regulators after showing it helped patients live longer without the disease ...

Roche RHHBY obtained a Breakthrough Therapy Designation for its investigational oral therapy inavolisib for treating adult breast cancer patients in the United States. The FDA granted this ...

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) said that an advisory panel of the European Medicines Agency (EMA), endorsed its Itovebi ...

Roche, hoping to carve out a standard-of-care spot for its PI3K inhibitor Itovebi, now has another leg to stand on with new ...

The green light comes after a six-month priority review by the FDSA and is a big step up for Roche’s drug, which has the opportunity to build a presence in breast cancer ahead of earlier-to ...

A group of advisers to the Food and Drug Administration said Roche Holding AG needs to study its blood cancer treatment in ...

A study involving an experimental cancer drug being developed by Roche Holding (RHHBY, ROG.VX) showed it delayed disease progression in women with a specific type of breast cancer compared to ...

The Itovebi, Ibrance, and fulvestrant combination demonstrated improved survival outcomes versus placebo in a Phase III trial.

Swiss pharma company Roche ... FDA Priority Review status for a Perjeta (pertuzumab) regimen to be used before surgery (neoadjuvant treatment) in people with HER2-positive early stage breast cancer.